J. Goldman & Co’s Foghorn Therapeutics FHTX Stock Holding History

J. Goldman & Co’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,488	Closed	-$388K	–	386
2022 Q1	$388K	Buy	25,488 +6,750	+36%	+$92.6K	0.02%	298
2021 Q4	$429K	Sell	18,738 -48,762	-72%	-$701K	0.02%	294
2021 Q3	$940K	Buy	+67,500	New	+$747K	0.05%	246

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

J. Goldman & Co's FHTX Position: Q2 2022 in Review

J. Goldman & Co sold out of Foghorn Therapeutics (FHTX) in Q2 2022, closing a stake of 25,488 shares — an estimated $388K sold.

J. Goldman & Co first reported a position in FHTX in Q3 2021 and held it in 3 quarters. The position peaked at $940K in Q3 2021. 60 funds tracked by Wall St. Rank hold FHTX as of Q2 2022.

J. Goldman & Co reported no remaining Foghorn Therapeutics position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 25,488 Foghorn Therapeutics shares in Q2 2022, an estimated $388K.
J. Goldman & Co first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 3 quarters.
J. Goldman & Co's Foghorn Therapeutics position peaked at $940K in Q3 2021.
60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.